Scientists trace genomic evolution of high-risk leukemia

Memphis, Tennessee, March 19, 2015

 

Whole exome sequencing of 20 pediatric ALL patients yielded important insights into the genetic basis of ALL treatment failure. The findings may lead to early detection of the mutations that drive ALL relapse.

By genomic sequencing of leukemia cells from relapsed patients at different stages, scientists have discovered key details of how acute lymphoblastic leukemia (ALL) cells mutate to survive chemotherapy. These mutations enable the cells to proliferate, causing relapse and often death.

The findings are important because ALL is a leading cause of cancer deaths in children, with 15 percent of ALL patients relapsing with poor survival. The researchers said their findings will lead to new tests to monitor children in remission and to detect signs of relapse.

The research was published in the March 19 issue of the journal Nature Communications. Leading the research team were corresponding authors Charles Mullighan, M.D., MBBS(Hons), a member of the St. Jude Children’s Research Hospital Department of Pathology; Jinghui Zhang, Ph.D., a member of the St. Jude Department of Computational Biology; and Stephen Hunger, M.D., director of the Center for Childhood Cancer Research at The Children’s Hospital of Philadelphia.

In their study, the researchers analyzed the genomes of cells from 20 children who had ALL that returned following treatment. Importantly, the researchers analyzed cell samples taken at three stages—diagnosis, remission and relapse.

Thus, the scientists could analyze in detail the genomes of the cells at the different stages, determining the mutations that drove the relapse of leukemia. Cancers such as leukemia are not a homogeneous disease. Rather they are a witch’s brew of different dividing cancer cells, called “clones,” with distinctive sets of mutations. While chemotherapy might kill almost all the clones, some might have escaped therapy, leaving them to multiply to cause relapse.

“In our study we wanted to find out the underlying mechanism leading to cancer relapse,” Zhang said. “When the cancer recurs, is it a completely different cancer, or is it an extension, or change, arising from pre-existing cancer?”

New genomic analytical technologies enabled the scientists to detect with great sensitivity the mutations in both the “rising” and “falling” clones at the different stages. Previous studies have attempted to work backward by genomically analyzing the relapsed clone to try to trace back its origin. However, such analysis would miss the low levels of the cells that, at diagnosis, would ultimately cause relapse.

The researchers’ genomic analysis of the cancer clonal cells pinpointed the mutations that drove the leukemia. They also characterized how diverse those mutations were at both diagnosis and relapse—finding that the cancer cells were mutating just as wildly and diversely throughout the cancer process.

“This finding was interesting, because most people think that the clone that has the most mutations is more likely to survive therapy and evolve, but that doesn’t seem to be the case,” Zhang said.

A key finding was that in most cases relapse of the cancer was driven by a minor clone, or “subclone,” present at an extremely low level, that survived therapy. This finding has implications for genomic analysis of ALL after a patient’s treatment, to determine the likelihood of relapse.

Jinghui Zhang, PhD

Jinghui Zhang, Ph.D.

“When we are analyzing for the level of minimum residual disease in monitoring remission in patients, we should not only pay attention to the mutations in the predominant clone,” said Zhang. “We should also be tracking what kinds of mutations exist in the minor subclones.”

In their analysis, the researchers identified seven specific genes that were highly likely to be mutated in relapsed disease. Researchers at St. Jude and elsewhere are currently exploring the biological functions of the relapse-related genes, and the results may aid in developing ways to identify drugs to target their function.

More broadly, the methodology of highly sensitive genomic analysis of cancer cells that Zhang and her colleagues developed can be applied to explore the evolution of other cancers.

The first author of the study was Xiaotu Ma, Ph.D., of St. Jude Computational Biology. The other authors are Michael Edmonson, Donald Yergeau, Michael Rusch, Guangchun Song, John Easton, Jing Ma, Bhavin Vadodaria, Gang Wu, Mary Relling and James R. Downing, all of St. Jude; Panduka Nagahawatte, formerly of St. Jude; Donna Muzny, Oliver Hampton, David Wheeler and HarshaVardhan Doddapaneni, all of Baylor College of Medicine, Houston; Richard Harvey, I-Ming Chen and Cheryl Willman, all of University of New Mexico, Albuquerque; William Carroll, of New York University; Julie Gastier-Foster, of Nationwide Children's Hospital and Ohio State University College of Medicine, Columbus; Malcolm Smith, Jaime Guidry Auvil and Daniela Gerhard, all of the National Cancer Institute (NCI), Bethesda, MD; Meenakshi Devidas, of the University of Florida, Gainesville; and Mignon Loh, of the University of California, San Francisco.

The research was a collaborative project of the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project, the Children’s Oncology Group and the NCI’s Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative.

The research was funded in part by the Pediatric Cancer Genome Project, including Kay Jewelers, a lead sponsor; grants (CA98543, CA21765, CA98413, CA114766) from the NCI at the National Institutes of Health; a contract (N261200800001E) from NCI; the St. Baldrick’s Foundation and ALSAC.

St. Jude Children’s Research Hospital

St. Jude Children’s Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow the hospital on Twitter and Instagram at @stjuderesearch.